Profile cover photo
Profile photo
MetaStat Inc.
1 follower -
MetaStat, Inc. (OTCQB: MTST) develops and commercializes diagnostic tests for risk of cancer metastasis, companion diagnostics and anti-metastatic drugs.
MetaStat, Inc. (OTCQB: MTST) develops and commercializes diagnostic tests for risk of cancer metastasis, companion diagnostics and anti-metastatic drugs.

1 follower
About
MetaStat Inc.'s posts

Post has attachment
Metastat announces results from two clinical studies of its MetaSite Breast™ test reported at the 39th San Antonio Breast Cancer Symposium (SABCS) demonstrating that the MetaSite Score was significantly associated with increased risk of distant metastasis in Hormone Receptor (HR-positive), HER2-negative Early Stage Breast Cancer (ESBC). “We are pleased to present positive results from two prospectively designed, retrospective studies of MetaSite Breast™ confirming the clinical validity of the association between MetaSite Score and distant cancer metastasis,” said Douglas A. Hamilton, MetaStat’s President and CEO. Click to learn more.

Post has attachment
Aggressive cancer that metastasizes or spreads from a primary tumor through the bloodstream to other areas of the body is responsible for approximately 90% of all solid tumor cancer related deaths. MetaStat's focus is on preventing aggressive tumors from spreading. Learn more on our website:

Post has attachment
Over two-thirds of healthcare professionals surveyed reported improved patient outcomes from personalized medicine initiatives. Learn more from ZDNet.

Post has attachment
MetaStat's product development strategy is based on identifying patients most at risk for cancer metastasis and targeting the underlying mechanisms that drive the metastatic cascade.

Post has attachment
Learn more about genomic testing & precision medicine's role in the future of oncology in this recent Oncology Times article.

Post has attachment
MetaStat is a pre-commercial biotechnology company focused on the development and commercialization of diagnostic tests that are prognostic for risk of cancer metastasis, companion diagnostics to predict drug response, and anti-metastatic drugs. Learn more on our website.

Post has attachment
A new study indicates that advances in precision medicine, such as tests to help reduce overtreatment in breast cancer patients, have improved breast cancer treatment.

Post has attachment
Boston hospitals join sweeping national effort to gather medical data as part of their participation in the national Precision Medicine Initiative.

Post has attachment
Precision medicine has grown rapidly in the past several years in part due to advances in gene sequencing and molecular-level diagnoses. Click to learn more:

Post has attachment
Wait while more posts are being loaded